CRESCENT BIOPHARMA, INC. — Director's Dealing 2019

Jan 23, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2019-01-17

Reporting Person: Thackray Helen M. (SVP Clinical Development, CMO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-17	Employee Stock Option (right to buy)	$10.59	A	100000	Acquired	2029-01-16	Common Stock (100000)	Direct

Footnotes

F1: One-fourth of the shares underlying this option vest on January 17, 2020 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.